Expression of Glutamate Transporters in Alcohol Withdrawal

Abstract

Introduction: The study aimed to investigate the expression of glutamate transporters during withdrawal in the alcohol-dependent patients.

Method: The study consisted of 20 male inpatient alcoholics during the withdrawal period and 20 healthy controls. Expressions of glutamate transporters, namely the excitatory amino acid transporter 2 (EAAT2) and EAAT3, in white blood cells were measured with the real-time polymerase chain reaction (RT-PCR) method in early (first day) and late (28^th day) withdrawal in alcoholic patients and once in the controls.

Results: EAAT2 and EAAT3 expressions in the patients during both early and late withdrawal were higher than those of the controls. There was no difference in the EAAT2 and EAAT3 levels of the patients between early and late abstinence.

Discussion: The study revealed an upregulation of glutamate transporters EAAT2 and EAAT3 during early and late withdrawal in patients with alcohol withdrawal.

Key words

alcohol withdrawal - glutamate - EAAT

• References

• 1 Gonzalez J, Jurado-Coronel JC, Avila MF et al. NMDARs in neurological diseases: a potential therapeutic target. Int J Neurosci 2015; 125: 315-327
• 2 Nakagawa T, Kaneko S. SLC1 glutamate transporters and diseases: psychiatric diseases and pathological pain. Curr Mol Pharmacol 2013; 6: 66-73
• 3 Krystal JH, Petrakis IL, Mason G et al. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther 2003; 99: 79-94
• 4 Holmes A, Spanagel R, Krystal JH. Glutamatergic targets for new alcohol medications. Psychopharmacology (Berl) 2013; 229: 539-554
• 5 Rao PS, Sari Y. Glutamate transporter 1: target for the treatment of alcohol dependence. Curr Med Chem 2012; 19: 5148-5156
• 6 Spanagel R, Vengeliene V. New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci 2013; 13: 583-609
• 7 Arriza JL, Fairman WA, Wadiche JI et al. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 1994; 14: 5559-5569
• 8 Danbolt NC. Glutamate uptake. Prog Neurobiol 2001; 65: 1-105
• 9 Skerry TM, Genever PG. Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci 2001; 22: 174-181
• 10 Zoia C, Cogliati T, Tagliabue E et al. Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimer’s disease. Neurobiol Aging 2004; 25: 149-157
• 11 Begni B, Tremolizzo L, D'Orlando C et al. Substrate-induced modulation of glutamate uptake in human platelets. Br J Pharmacol 2005; 145: 792-799
• 12 Kryger R, Wilce PA. The effects of alcoholism on the human basolateral amygdala. Neuroscience 2010; 167: 361-371
• 13 Sari Y. Potential therapeutic role of glutamate transporter 1 for the treatment of alcohol dependence. OA Alcohol 2013; 1: 6
• 14 Sari Y. Role of glutamate transporter 1 in the attenuation of alcohol intake. Front Neurosci 2014; 8: 200
• 15 Sari Y, Sakai M, Weedman JM et al. Ceftriaxone, a beta-lactam antibiotic, reduces ethanol consumption in alcohol-preferring rats. Alcohol Alcohol 2011; 46: 239-246
• 16 Qrunfleh AM, Alazizi A, Sari Y. Ceftriaxone, a beta-lactam antibiotic, attenuates relapse-like ethanol-drinking behavior in alcohol-preferring rats. J Psychopharmacol 2013; 27: 541-549
• 17 Sari Y, Sreemantula SN. Neuroimmunophilin GPI-1046 reduces ethanol consumption in part through activation of GLT1 in alcohol-preferring rats. Neuroscience 2012; 227: 327-335
• 18 Alhaddad H, Kim NT, Aal-Aaboda M et al. Effects of MS-153 on chronic ethanol consumption and GLT1 modulation of glutamate levels in male alcohol-preferring rats. Front Behav Neurosci 2014; 8: 366
• 19 Selzer ML. The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry 1971; 127: 1653-1658
• 20 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
• 21 Sullivan JT, Swift RM, Lewis DC. Benzodiazepine requirements during alcohol withdrawal syndrome: clinical implications of using a standardized withdrawal scale. J Clin Psychopharmacol 1991; 11: 291-295
• 22 Aoyama K, Nakaki T. Neuroprotective properties of the excitatory amino acid carrier 1 (EAAC1). Amino Acids 2013; 45: 133-142